Drug Trial Radar · NCT06413498
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
452
Actual
Start
Aug 23, 2024
Primary completion
Jul 2028
Study completion Jul 2031
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Arcellx, Inc.
- First posted
- May 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Conditions
- Multiple Myeloma
Interventions
Anitocabtagene AutoleucelDrug
A single infusion of CAR+ transduced autologous T cells
CyclophosphamideDrug
Administered intravenously
FludarabineDrug
Administered intravenously
PomalidomideDrug
Tablet administered orally
BortezomibDrug
Administered intravenously or subcutaneously
DexamethasoneDrug
Tablet administered orally
DaratumumabDrug
Administered intravenously or subcutaneously
CarfilzomibDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to 4 years
- Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 MonthsTime frame: Up to 9 months
Locations
117 sites in 15 countries. Site status is shown where the registry gives one.
Banner MD Anderson Cancer Center
Gilbert, Arizona
Mayo Clinic Hospital
Gilbert, Arizona
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
USC/Norris Comprehensive Cancer Center
Los Angeles, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
UC San Diego Moores Cancer Center
San Diego, California
UCLA Hematology/Oncology (Bowyer Infusion Clinic)
Santa Monica, California
Stanford Cancer Institute
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
Sylvester Comprehensive Cancer Center
Coral Gables, Florida
Mayo Clinic
Jacksonville, Florida
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta
Newnan, Georgia
St. Luke's Cancer Institute
Boise, Idaho
University of Illinois Hospital and Health Sciences System
Chicago, Illinois
IU Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
Norton Cancer Institute, St. Matthews Campus
Louisville, Kentucky
Ochsner Clinical Foundation
New Orleans, Louisiana
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Boston Medical Center
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Corewell Health - Lemmen-Holton Cancer Pavilion
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy
Omaha, Nebraska
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
New Mexico Cancer Research Alliance
Albuquerque, New Mexico
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Weill Cornell Medicine - New York Presbyterian Hosptial
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
Novant Health Cancer Institute Hematology- Forsyth
Winston-Salem, North Carolina
University of Cincinnati Cancer Center
Cincinnati, Ohio
Oregon Health and Science University
Portland, Oregon
University of Tennessee Medical Center
Knoxville, Tennessee
Baptist Cancer Center
Memphis, Tennessee
Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research
Nashville, Tennessee
Henry-Joyce Cancer Clinic
Nashville, Tennessee
St. David's South Austin Medical Center
Austin, Texas
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.